On April 7, according to The Information and Eric Newcomer, AI giant Anthropic is continuing its push into healthcare with the acquisition of Coefficient Bio, a previously little-known AI biotechnology startup, in a $400 million stock deal. The acquisition was confirmed by people familiar with the matter, and Coefficient’s PitchBook page also reflects the $400 million transaction.In early April, Anthropic, the U.S. AI unicorn, announced the completion of a $30 billion Series G funding round, valuing the company at $380 billion—a sharp increase from its $183 billion valuation in the previous Series F round. In less than three years since its founding, it has achieved $14 billion in annualized revenue, with growth of more than 10-fold each year over the past three years.

Aris Theologis is CEO and co-founder of Coefficient. He previously served as Chief Business Officer of Evozyne and Vice President of Paragon Biosciences. He also has extensive experience in AI partnerships; during his tenure at Evozyne, he built and expanded collaborations with NVIDIA. Headquartered in New York, Coefficient was founded in 2025 and has six employees, with Dimension as its investor. Nathan Frey later joined as co-founder and Chief Technology Officer; he was Chief Scientist at Biogen until last September. Joyce Hong, the third co-founder, worked at Roivant Sciences for nearly five years. Coefficient uses artificial intelligence to improve efficiency in drug discovery and biological research.
Anthropic has been expanding its healthcare business over the past six months, launching Claude for Life Sciences in October and Claude for Healthcare in January. The company has also announced new features for life sciences, with its products covering everything from preclinical R&D to clinical operations and regulatory affairs.
Eric Kauderer Abrams, Head of Biology and Life Sciences at Anthropic, stated that healthcare and life sciences are among the company’s largest strategic bets. For life sciences, the goal is to ensure that Anthropic’s models have all the capabilities from early-stage discovery to translation and commercialization, and that they can integrate with the tools scientists and life science professionals use daily.
Anthropic’s entry into biotechnology and healthcare follows similar moves by OpenAI, the company behind ChatGPT, including ChatGPT Health, a hub that allows users to upload medical records, and OpenAI for Healthcare, a suite of tools for healthcare enterprises.